CN112020506B - 新生霉素类似物与脯氨酸的共晶体形式 - Google Patents

新生霉素类似物与脯氨酸的共晶体形式 Download PDF

Info

Publication number
CN112020506B
CN112020506B CN201980011980.6A CN201980011980A CN112020506B CN 112020506 B CN112020506 B CN 112020506B CN 201980011980 A CN201980011980 A CN 201980011980A CN 112020506 B CN112020506 B CN 112020506B
Authority
CN
China
Prior art keywords
proline
crystal
crystals
concentration
starting composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980011980.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN112020506A (zh
Inventor
江昕
约翰·艾伦·沃林
梅拉妮·J·贝维尔
克里斯托弗·S·西迪克
贾里德·P·斯米特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Reata Pharmaceuticals Inc
Original Assignee
Reata Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reata Pharmaceuticals Inc filed Critical Reata Pharmaceuticals Inc
Priority to CN202410935084.1A priority Critical patent/CN118894894A/zh
Publication of CN112020506A publication Critical patent/CN112020506A/zh
Application granted granted Critical
Publication of CN112020506B publication Critical patent/CN112020506B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/207—Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201980011980.6A 2018-02-07 2019-02-01 新生霉素类似物与脯氨酸的共晶体形式 Active CN112020506B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410935084.1A CN118894894A (zh) 2018-02-07 2019-02-01 新生霉素类似物与脯氨酸的共晶体形式

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862627570P 2018-02-07 2018-02-07
US62/627,570 2018-02-07
PCT/US2019/016304 WO2019156907A1 (en) 2018-02-07 2019-02-01 Co-crystal forms of a novobiocin analog and proline

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410935084.1A Division CN118894894A (zh) 2018-02-07 2019-02-01 新生霉素类似物与脯氨酸的共晶体形式

Publications (2)

Publication Number Publication Date
CN112020506A CN112020506A (zh) 2020-12-01
CN112020506B true CN112020506B (zh) 2024-10-11

Family

ID=65444361

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980011980.6A Active CN112020506B (zh) 2018-02-07 2019-02-01 新生霉素类似物与脯氨酸的共晶体形式
CN202410935084.1A Pending CN118894894A (zh) 2018-02-07 2019-02-01 新生霉素类似物与脯氨酸的共晶体形式

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410935084.1A Pending CN118894894A (zh) 2018-02-07 2019-02-01 新生霉素类似物与脯氨酸的共晶体形式

Country Status (19)

Country Link
US (3) US10717755B2 (https=)
EP (1) EP3749675B1 (https=)
JP (3) JP2021512910A (https=)
KR (2) KR20240155354A (https=)
CN (2) CN112020506B (https=)
AR (1) AR114245A1 (https=)
AU (3) AU2019217821B2 (https=)
BR (1) BR112020016205A2 (https=)
CA (2) CA3226385A1 (https=)
CL (2) CL2020002051A1 (https=)
CO (1) CO2020009761A2 (https=)
EA (1) EA202091885A1 (https=)
IL (2) IL276583B2 (https=)
MX (2) MX2020008326A (https=)
MY (1) MY209803A (https=)
PE (1) PE20211446A1 (https=)
SG (1) SG11202007530XA (https=)
TW (2) TWI797249B (https=)
WO (1) WO2019156907A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3749675B1 (en) 2018-02-07 2025-12-31 Reata Pharmaceuticals, Inc. CO-CRISTALLIN FORMS OF A NOVOBIOCIN AND PROLINE ANALOGUE
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
CN115181146B (zh) * 2021-04-02 2024-06-04 浙江普洛家园药业有限公司 一种新生霉素的提取工艺

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104271587A (zh) * 2012-02-09 2015-01-07 堪萨斯大学 Hsp90C端抑制剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9029369B2 (en) * 2010-09-23 2015-05-12 Nuformix Limited Aprepitant L-proline composition and cocrystal
TWI542596B (zh) * 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
CA2892832C (en) * 2011-11-25 2020-04-14 Nuformix Technologies Limited Aprepitant l-proline solvates - compositions and cocrystals
EP2602249B1 (en) * 2011-12-06 2015-08-12 F.I.S. Fabbrica Italiana Sintetici S.p.A. Synthesis of rosuvastatin by means of co-crystals
EP2890704B1 (en) * 2012-08-31 2018-02-28 Novartis AG 2'-ethynyl nucleoside derivatives for treatment of viral infections
TW201512201A (zh) * 2013-03-14 2015-04-01 Forum Pharmaceuticals Inc 化合物的多晶型及鹽類
MX388516B (es) * 2014-06-24 2025-03-20 Univ Kansas Bifenil amidas con grupos éter modificados como inhibidores de hsp90 e inductores de hsp70.
KR20170060035A (ko) * 2014-09-30 2017-05-31 지앙수 헨그루이 메디슨 컴퍼니 리미티드 나트륨 글루코스 공동운반체 2 억제제의 ｌ- 프롤린 화합물, 및 ｌ- 프롤린 화합물의 모노하이드레이트 및 결정
EP3749675B1 (en) 2018-02-07 2025-12-31 Reata Pharmaceuticals, Inc. CO-CRISTALLIN FORMS OF A NOVOBIOCIN AND PROLINE ANALOGUE

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104271587A (zh) * 2012-02-09 2015-01-07 堪萨斯大学 Hsp90C端抑制剂

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Development of a pharmaceutical cocrystal with solution crystallization technology: Preparation, characterization, and evaluation of myricetin-proline cocrystals;Mingyu Liu等;European Journal of Pharmaceutics and Biopharmaceutics;第107卷;151-159 *
L.Roy等.Pharmaaceutical salts and Co-crystals.RSC,2012,247-279. *
The role of cocrystals in pharmaceutical science;Ning Shan等;Drug Discovery Today;第13卷(第9/10期);440-446 *

Also Published As

Publication number Publication date
TWI868593B (zh) 2025-01-01
IL276583A (en) 2020-09-30
JP2026012851A (ja) 2026-01-27
US11401294B2 (en) 2022-08-02
EA202091885A1 (ru) 2021-01-15
TWI797249B (zh) 2023-04-01
AU2022283638B2 (en) 2024-07-25
CA3226385A1 (en) 2019-08-15
CN112020506A (zh) 2020-12-01
IL315865A (en) 2024-11-01
US20190241599A1 (en) 2019-08-08
MY209803A (en) 2025-08-05
MX2022012856A (es) 2022-11-30
SG11202007530XA (en) 2020-09-29
AU2022283638A1 (en) 2023-02-02
PE20211446A1 (es) 2021-08-05
MX2020008326A (es) 2020-09-28
CL2022003784A1 (es) 2023-06-09
CL2020002051A1 (es) 2021-02-19
NZ767558A (en) 2024-11-29
AR114245A1 (es) 2020-08-12
IL276583B1 (en) 2024-11-01
JP2021512910A (ja) 2021-05-20
EP3749675B1 (en) 2025-12-31
US20240043465A1 (en) 2024-02-08
KR102718111B1 (ko) 2024-10-17
US10717755B2 (en) 2020-07-21
WO2019156907A1 (en) 2019-08-15
BR112020016205A2 (pt) 2020-12-15
CA3090646C (en) 2024-02-27
TW201945381A (zh) 2019-12-01
JP2024001167A (ja) 2024-01-09
AU2019217821B2 (en) 2022-09-08
AU2024227646A1 (en) 2024-11-14
CO2020009761A2 (es) 2020-10-30
CN118894894A (zh) 2024-11-05
KR20200141985A (ko) 2020-12-21
TW202323267A (zh) 2023-06-16
AU2019217821A1 (en) 2020-09-24
EP3749675A1 (en) 2020-12-16
KR20240155354A (ko) 2024-10-28
CA3090646A1 (en) 2019-08-15
US20200347088A1 (en) 2020-11-05
IL276583B2 (en) 2025-03-01
TW202510893A (zh) 2025-03-16

Similar Documents

Publication Publication Date Title
EP2753603B1 (en) Polymorphic form of pridopidine hydrochloride
US20240043465A1 (en) Co-crystal forms of a novobiocin analog and proline
KR20160118204A (ko) 2-하이드록시-6-((2-(1-이소프로필-1h-피라졸-5-일)피리딘-3-일)메톡시)벤즈알데하이드의 유리 염기의 결정성 다형체
US20160068530A1 (en) Solid state forms of vemurafenib and vemurafenib salts
US20260022115A1 (en) Polymorphic forms of a substituted-quinoxaline-type bridged-piperdine compound
US12473277B2 (en) Solid forms of a modulator of hemoglobin
HK40119275A (zh) 新生霉素类似物与脯氨酸的共晶体形式
TWI915111B (zh) 新生黴素（ｎｏｖｏｂｉｏｃｉｎ）類似物及脯胺酸之共晶型
EA049105B1 (ru) Формы сокристаллов аналога новобиоцина и пролина
RU2838992C2 (ru) Кристаллические формы ингибитора янус-киназы
EA043335B1 (ru) Формы сокристаллов аналога новобиоцина и пролина
WO2026018176A1 (en) 2-(4-chloro-2 methoxyphenyl)-2-((3-methoxy-5-(methylsulfonyl)phenyl)amino)-1-(5-(trifluoro¬methoxy)-1h-indol-3-yl)ethanone and pharmaceutical compositions comprising the same
TW200302830A (en) Anhydrate/hydrate of an erythromycin derivative and processes for preparing said anhydrate/hydrate
HK1199728B (en) Polymorphic form of pridopidine hydrochloride

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant